PharmaCyte Biotech (PMCBD) Stock Price, News & Analysis

Company Overview

PharmaCyte Biotech is a clinical-stage biotechnology company focused on developing innovative cellular therapies for cancer and potentially other chronic diseases. Utilizing its proprietary Cell-in-a-Box® encapsulation technology, the company engineers live cells to carry and activate therapeutic agents directly at the site of disease. This approach aims to enhance the efficacy of existing prodrugs while minimizing systemic toxicity, offering a novel treatment pathway distinct from traditional chemotherapy.

The company’s lead program targets locally advanced, inoperable pancreatic cancer. In collaboration with Austrianova and academic partners, PharmaCyte has completed Phase 2A clinical studies in Australia and is progressing toward pivotal trials in the United States. The encapsulated cells are designed to convert a nontoxic prodrug into an active cancer-killing agent within the tumor microenvironment, potentially improving outcomes for patients who have limited treatment options.

Founded in 2005 and headquartered in Henderson, Nevada, with research facilities in Palm Desert, California, PharmaCyte Biotech has navigated a series of strategic collaborations and regulatory milestones. Under the leadership of President and Chief Executive Officer Kenneth L. Waggoner, M.D., the company has expanded its pipeline to include potential applications in cholangiocarcinoma and other solid tumors. Management’s expertise spans clinical development, regulatory affairs, and cell biology, positioning PharmaCyte to advance its technology through late-stage trials.

Looking ahead, PharmaCyte Biotech is exploring opportunities to apply its encapsulation platform to additional indications such as diabetes and osteoarthritis, where localized enzyme activation could offer therapeutic benefits. The company continues to seek partnerships and funding to support its clinical development programs, with the goal of bringing its first therapy to market and establishing a new paradigm in targeted cellular medicine.

Key Stats

• Today's Range: $1.00 to $1.06
• 50-Day Range: $1.01 to $1.12
• 52-Week Range: $5.56 to $55.50
• Volume: 35,731 shs
• Average Volume: 8,831 shs
• Market Capitalization: $1.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PMCBD Stock Analysis - Frequently Asked Questions

How have PMCBD shares performed this year?

PharmaCyte Biotech's stock was trading at $1.55 at the start of the year. Since then, PMCBD stock has decreased by 33.5% and is now trading at $1.03.

How do I buy shares of PharmaCyte Biotech?

Shares of PMCBD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:PMCBD
• CIK: N/A
• Web: www.pharmacyte.com
• Phone: (917) 595-2850
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.83 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -49.09%
• Return on Assets: -43.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.90
• Quick Ratio: 4.90

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,671,000
• Free Float: N/A
• Market Cap: $1.70 million
• Optionable: Not Optionable
• Beta: 0.27